Categories: Artificial IntelligenceDesignDevelopmentDrugLearnPlatform
The name ENSEM connotes innovations in integrating groundbreaking technologies to decipher structural ENSEMbles and kinetics for drug design. ENSEM is a pioneering drug discovery and development company that leverages its unique Kinetic Ensemble™ platform to develop innovative small molecule precision medicines for oncology, with potential expansion into genetic disorders and other disease areas. ENSEM integrates computational and AI deep learning methodologies with advanced experimental techniques to identify non-obvious binding pockets and accelerate structure-based drug design, with a focus on high-value and difficult-to-drug targets.
Investors 1
Mentions in press and media 2
| Date | Title | Description |
| 08.04.2022 | Ensem Therapeutics Raises $67M in Series A Financing | Ensem Therapeutics, a Boston, MA-based biotechnology company, raised $67M in Series A funding.
The round was led by GGV Capital, with participation from Pavilion Capital, Cenova Capital, Mitsui & Co. Global Investment, and CBC Group.
Th... |
| 07.04.2022 | ENSEM Therapeutics, a CBC Group-Incubated Biopharma Company, Raises $67 Million in Series A Financing to Develop Small Molecule Medicines for Difficult-to-Drug Targets | BOSTON, April 7, 2022 /PRNewswire/ -- ENSEM Therapeutics Inc. (ENSEM), a Boston-based biotechnology company focusing on high value and difficult-to-drug oncology targets, announced today the closing of a series A2 financing. Incubated by CB... |
Reviews 0
